I
Intersect ENT
Intersect ENT - Propel Mometasone Furoate Implant
About Intersect ENT
Intersect ENT operates in the healthcare sector, focusing on innovative solutions for chronic sinusitis. The company's core technology is a bioabsorbable drug release platform, which is utilized in their sinus implants. These implants are designed to offer mechanical support and localized drug delivery, enhancing both patient experience and surgical outcomes. Intersect ENT primarily serves patients with chronic sinusitis, as well as the healthcare professionals who treat them. The company generates revenue through the sale of its specialized sinus implants and related products. Its business model revolves around continuous innovation and clinical validation to maintain a competitive edge in the ear, nose, and throat (ENT) therapy market. Intersect ENT's market includes hospitals, clinics, and specialized ENT practices. The company also emphasizes a strong corporate culture, offering competitive salaries, benefits, and opportunities for professional growth to attract top talent.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2003
- Headquarters
- Menlo Park, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
32 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intersect ENT on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intersect ENT on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.